![]() ![]() This limitation is even more apparent for immediate release polymers which count for approximately 70% of all oral dosage forms. However, most pharmaceutical grade polymers lack such attributes, being either too brittle so that the filaments break in the motor gear or too soft to be pushed by the drive gear hindering printing. For successful printing filaments must possess mechanical properties, flexibilities and melt viscosities within a narrow range. For melt extrusion-based 3D printing, the most commonly quoted limitation of the technique is the lack of suitable polymers for FDM printing. Within this research space, a range of 3D printing methods have been reported, including fused deposition modelling (FDM), selective laser sintering (SLS), binder jetting (BJ), semi-solid extrusion (SSE) and stereolithography (SLA). The advantages of using 3D printing over traditionally mass produced ‘one-size fits all’ conventional solid dosage forms have been widely reported with flexible AM techniques enabling on-demand manufacture of personalised medicine tailored for individual patients’ clinical needs in terms of both dose and drug release profile. Despite the huge increase in accessibility to 3D printers and large reductions in costs there is still only one 3D printed oral dosage form on the market, Spritam™ which gained FDA approval in 2015. Whilst some AM technologies such as binder jetting and selective laser melting are already used in high cost, low volume applications such as prosthetic and dental implant manufacture, only in the past few years have lower cost, high volume applications such as pharmaceutical drug delivery become viable. The results of this study demonstrated that this new printing method can be used as a potentially valuable alternative for decentralised pharmaceutical solid dosage form manufacturing.Īdditive manufacturing (AM) is a rapidly growing field encompassing many 3D printing technologies that have the potential to revolutionise the medical and pharmaceutical sector. ![]() ![]() This is the first report of thermal droplet deposition printing via direct granule feeding. The level of infill density of the porous tablets had a significant effect on their in vitro drug release performance. The printing quality and performances of the porous tablets were confirmed to be highly compliant with the pharmacopeia requirement. The drug was confirmed to be molecularly dispersed in the printed tablets. Using the method developed by this study, Eudragit E PO was printed with a model drug into tablets with infills ranging from 30–100%, without additives. The physicochemical properties and in vitro drug release performance of the granules and the printed tablets were fully characterised. The flow and feedability of the granules were evaluated. Wet granulation was used to produce drug loaded granules as the feedstock. MethodsĮudragit® E PO was used as the model polymer, which is well-known to be not FDM printable without additives. To develop a new direct granule fed 3D printing method for manufacturing pharmaceutical solid dosage forms with porous structures using a thermal droplet deposition technology. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |